Watch a webinar as experts on tenosynovial giant cell tumor (TGCT) share an overview of TGCT and a simple summary of the MOTION study. ROMVIMZA is a prescription medicine used to treat adults with ...
Real-world cardiac evaluation in patients with advanced lung cancer who received immune checkpoint inhibitors. Anlotinib in combination with epirubicin followed by maintenance anlotinib versus placebo ...
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2% Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary ...
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced that the Phase III MANEUVER trial of pimicotinib, an investigational medicine being developed by ...
Vimseltinib is the first and only therapy with marketing authorization for the treatment of TGCT in the European Union Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: ...
On August 8, 2025, the FDA granted accelerated approval to zongertinib for adult patients with unresectable or metastatic ...
An Ono Pharma drug for a type of tumor affecting tissues of the joints is now FDA approved, giving the Japanese company a product with dosing and safety advantages over the Daiichi Sankyo product that ...
The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza TM) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the tissue ...
Tenosynovial giant cell tumor (TGCT) is a group of rare tumors. They are usually benign (not cancer) and tend to occur in people between 25 to 50 years old. The tumors affect areas of the joints and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback